- Home
- BOLD vs CALC Comparison
BOLD vs CALC Comparison
Compare BOLD & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- CALC
- Stock Information
- Founded
- BOLD 2018
- CALC 2011
- Country
- BOLD United States
- CALC United States
- Employees
- BOLD N/A
- CALC N/A
- Industry
- BOLD
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- BOLD
- CALC Health Care
- Exchange
- BOLD Nasdaq
- CALC Nasdaq
- Market Cap
- BOLD 30.3M
- CALC 25.2M
- IPO Year
- BOLD 2024
- CALC N/A
- Fundamental
- Price
- BOLD $1.42
- CALC $1.55
- Analyst Decision
- BOLD Buy
- CALC Strong Buy
- Analyst Count
- BOLD 3
- CALC 3
- Target Price
- BOLD $22.50
- CALC $16.33
- AVG Volume (30 Days)
- BOLD 69.6K
- CALC 60.4K
- Earning Date
- BOLD 05-12-2025
- CALC 05-12-2025
- Dividend Yield
- BOLD N/A
- CALC N/A
- EPS Growth
- BOLD N/A
- CALC N/A
- EPS
- BOLD N/A
- CALC N/A
- Revenue
- BOLD N/A
- CALC N/A
- Revenue This Year
- BOLD N/A
- CALC N/A
- Revenue Next Year
- BOLD N/A
- CALC N/A
- P/E Ratio
- BOLD N/A
- CALC N/A
- Revenue Growth
- BOLD N/A
- CALC N/A
- 52 Week Low
- BOLD $1.06
- CALC $1.45
- 52 Week High
- BOLD $12.65
- CALC $6.27
- Technical
- Relative Strength Index (RSI)
- BOLD N/A
- CALC 32.53
- Support Level
- BOLD N/A
- CALC $1.45
- Resistance Level
- BOLD N/A
- CALC $1.67
- Average True Range (ATR)
- BOLD 0.00
- CALC 0.15
- MACD
- BOLD 0.00
- CALC -0.01
- Stochastic Oscillator
- BOLD 0.00
- CALC 15.38
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.